CO6400199A2 - Formulaciones inyectables de toxina botulínica - Google Patents

Formulaciones inyectables de toxina botulínica

Info

Publication number
CO6400199A2
CO6400199A2 CO11094674A CO11094674A CO6400199A2 CO 6400199 A2 CO6400199 A2 CO 6400199A2 CO 11094674 A CO11094674 A CO 11094674A CO 11094674 A CO11094674 A CO 11094674A CO 6400199 A2 CO6400199 A2 CO 6400199A2
Authority
CO
Colombia
Prior art keywords
botulinum toxin
clinical efficacy
injectable compositions
injectable formulations
botulin toxin
Prior art date
Application number
CO11094674A
Other languages
English (en)
Inventor
L Curtis Ruegg
F Hongran Stone
Jacob M Waugh
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42285690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6400199(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of CO6400199A2 publication Critical patent/CO6400199A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta invención proporciona composiciones inyectables novedosas con contenido de toxina botulínica, que pueden administrarse a un sujeto para varios propósitos terapéuticos, estéticos y/o cosméticos. Las composiciones inyectables contempladas por la invención exhiben una o más ventajas sobre las formulaciones convencionales de toxina botulínica, incluyendo antigenicidad reducida, una menor tendencia a experimentar difusión localizada indeseada luego de la inyección, una mayor duración de la eficacia clínica o potencia mejorada relativa, manifestación más rápida de la eficacia clínica, y/o estabilidad mejorada.
CO11094674A 2008-12-31 2011-07-28 Formulaciones inyectables de toxina botulínica CO6400199A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14206308P 2008-12-31 2008-12-31

Publications (1)

Publication Number Publication Date
CO6400199A2 true CO6400199A2 (es) 2012-03-15

Family

ID=42285690

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11094674A CO6400199A2 (es) 2008-12-31 2011-07-28 Formulaciones inyectables de toxina botulínica

Country Status (25)

Country Link
US (5) US9956435B2 (es)
EP (2) EP2379104B1 (es)
JP (6) JP5866202B2 (es)
KR (4) KR102179926B1 (es)
CN (2) CN102300584A (es)
AU (5) AU2009332947C1 (es)
BR (1) BRPI0923731B1 (es)
CA (1) CA2749757C (es)
CO (1) CO6400199A2 (es)
CY (1) CY1120137T1 (es)
DK (2) DK2379104T3 (es)
ES (2) ES2669020T3 (es)
HK (1) HK1256878A1 (es)
HR (1) HRP20180739T1 (es)
HU (1) HUE037595T2 (es)
IL (3) IL213668A (es)
LT (1) LT2379104T (es)
MX (1) MX2011007059A (es)
NO (1) NO2379104T3 (es)
PL (1) PL2379104T3 (es)
PT (1) PT2379104T (es)
RU (1) RU2011125775A (es)
SG (3) SG10202100698QA (es)
SI (1) SI2379104T1 (es)
WO (1) WO2010078242A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) * 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
BRPI0608249A2 (pt) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
MX2009007070A (es) * 2006-12-29 2009-07-10 Revance Therapeutics Inc Moleculas de transporte que utilizan los polipeptidos hiv-tat de secuencia inversa.
KR102088949B1 (ko) * 2007-07-26 2020-03-13 레반스 테라퓨틱스, 아이엔씨. 항미생물 펩티드, 조성물, 및 이용 방법
CN101868273B (zh) 2007-10-02 2014-10-15 莱蒙德尔有限公司 外部药泵
US9345836B2 (en) 2007-10-02 2016-05-24 Medimop Medical Projects Ltd. Disengagement resistant telescoping assembly and unidirectional method of assembly for such
US10420880B2 (en) 2007-10-02 2019-09-24 West Pharma. Services IL, Ltd. Key for securing components of a drug delivery system during assembly and/or transport and methods of using same
US7967795B1 (en) 2010-01-19 2011-06-28 Lamodel Ltd. Cartridge interface assembly with driving plunger
US9656019B2 (en) 2007-10-02 2017-05-23 Medimop Medical Projects Ltd. Apparatuses for securing components of a drug delivery system during transport and methods of using same
DK2271670T3 (en) 2008-03-14 2014-12-01 Allergan Inc IMMUNE BASED ACTIVITY ASSAYS WITH BOTULINUM TOXIN SEROTYPE A
US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
DK2379104T3 (en) * 2008-12-31 2018-04-30 Revance Therapeutics Inc Injectable botulinum toxin formulations
US20120107361A1 (en) 2009-06-25 2012-05-03 Revance Therapeutics ,Inc. Albumin-Free Botulinum Toxin Formulations
US10071198B2 (en) 2012-11-02 2018-09-11 West Pharma. Servicees IL, Ltd. Adhesive structure for medical device
US8157769B2 (en) 2009-09-15 2012-04-17 Medimop Medical Projects Ltd. Cartridge insertion assembly for drug delivery system
US10071196B2 (en) 2012-05-15 2018-09-11 West Pharma. Services IL, Ltd. Method for selectively powering a battery-operated drug-delivery device and device therefor
ES2688065T3 (es) * 2009-10-21 2018-10-30 Revance Therapeutics, Inc. Métodos y sistemas para purificar la neurotoxina botulínica no complejada
US10585098B2 (en) 2009-11-23 2020-03-10 The Johns Hopkins University Optimizing diagnostics for galactofuranose containing antigens
US10288611B2 (en) 2009-11-23 2019-05-14 The Johns Hopkins University Lateral flow device for diagnosing microbial infections
US8348898B2 (en) 2010-01-19 2013-01-08 Medimop Medical Projects Ltd. Automatic needle for drug pump
EP2569031B1 (en) * 2010-05-10 2017-10-11 Medimop Medical Projects Ltd. Low volume accurate injector
KR101134146B1 (ko) * 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
ES2641068T3 (es) * 2011-01-07 2017-11-07 Revance Therapeutics, Inc. Composición tópica que comprende una toxina botulínica y un colorante
USD702834S1 (en) 2011-03-22 2014-04-15 Medimop Medical Projects Ltd. Cartridge for use in injection device
US9072827B2 (en) 2012-03-26 2015-07-07 Medimop Medical Projects Ltd. Fail safe point protector for needle safety flap
MX370929B (es) * 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
US9421323B2 (en) 2013-01-03 2016-08-23 Medimop Medical Projects Ltd. Door and doorstop for portable one use drug delivery apparatus
US9011164B2 (en) 2013-04-30 2015-04-21 Medimop Medical Projects Ltd. Clip contact for easy installation of printed circuit board PCB
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US10107822B2 (en) 2013-12-16 2018-10-23 The Johns Hopkins University Interferon-gamma release assays for diagnosis of invasive fungal infections
ES2642916T3 (es) * 2014-06-06 2017-11-20 Galit KLEINER-FISMAN Toxina botulínica para su uso en el tratamiento de la paratonia
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
EP3174523B1 (en) * 2014-07-31 2020-07-01 Allergan, Inc. Formulations of biologics for intravesical instillation
KR20170093780A (ko) * 2014-09-02 2017-08-16 아메리칸 실버, 엘엘씨 보툴리눔 톡신 및 콜로이드 은 입자
RU2694820C9 (ru) * 2014-12-23 2019-08-12 Мерц Фарма Гмбх Унд Ко. Кгаа Контейнер, предварительно заполненный ботулиновым токсином
US10293120B2 (en) 2015-04-10 2019-05-21 West Pharma. Services IL, Ltd. Redundant injection device status indication
KR102099326B1 (ko) * 2015-04-13 2020-04-09 주식회사 엘지생활건강 폴리페놀 전달용 용해성 마이크로니들
PL3284506T3 (pl) 2015-04-13 2021-10-25 Lg Household & Health Care Ltd. Rozpuszczalna mikroigła zawierająca składnik do kontroli uwalniania neuroprzekaźników
US10149943B2 (en) 2015-05-29 2018-12-11 West Pharma. Services IL, Ltd. Linear rotation stabilizer for a telescoping syringe stopper driverdriving assembly
CN107683158B (zh) 2015-06-04 2021-05-14 麦迪麦珀医疗工程有限公司 用于药物释放装置的筒插入
US10576207B2 (en) 2015-10-09 2020-03-03 West Pharma. Services IL, Ltd. Angled syringe patch injector
US9987432B2 (en) 2015-09-22 2018-06-05 West Pharma. Services IL, Ltd. Rotation resistant friction adapter for plunger driver of drug delivery device
CN108472438B (zh) 2015-10-09 2022-01-28 西医药服务以色列分公司 至预填充的流体储存器的弯曲流体路径附加装置
SG10202004337WA (en) * 2015-10-29 2020-06-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
US11311674B2 (en) 2016-01-21 2022-04-26 West Pharma. Services IL, Ltd. Medicament delivery device comprising a visual indicator
EP3711793B1 (en) 2016-01-21 2021-12-01 West Pharma Services IL, Ltd. A method of connecting a cartridge to an automatic injector
US10646643B2 (en) 2016-01-21 2020-05-12 West Pharma. Services IL, Ltd. Needle insertion and retraction mechanism
US20170209553A1 (en) * 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
US11389597B2 (en) 2016-03-16 2022-07-19 West Pharma. Services IL, Ltd. Staged telescopic screw assembly having different visual indicators
JP6957525B2 (ja) 2016-06-02 2021-11-02 ウェスト ファーマ サービシーズ イスラエル リミテッド ３つの位置による針の退避
EP3490643B1 (en) 2016-08-01 2021-10-27 West Pharma. Services Il, Ltd. Anti-rotation cartridge pin
CN113577438B (zh) 2016-08-01 2023-05-23 西医药服务以色列有限公司 部分门关闭防止弹簧
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
EP3541358A1 (en) * 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US11260114B2 (en) * 2017-03-22 2022-03-01 Bonti, Inc. Botulinum neurotoxins for use in therapy
CN107185042B (zh) * 2017-04-29 2020-09-01 杭州维多利亚医疗美容医院有限公司 一种美容注射剂及其制备方法
KR20200006587A (ko) * 2017-05-18 2020-01-20 레반스 테라퓨틱스, 아이엔씨. 경부 근긴장이상증의 치료 방법
JP6921997B2 (ja) 2017-05-30 2021-08-18 ウェスト ファーマ サービシーズ イスラエル リミテッド ウェアラブル注射器のモジュラ駆動トレイン
US20210162026A1 (en) 2017-08-28 2021-06-03 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
KR20190038292A (ko) * 2017-09-29 2019-04-08 한국프라임제약주식회사 효능 지속시간이 연장된 보툴리눔 독소 조성물
US20200390871A1 (en) * 2017-11-03 2020-12-17 Revance Therapeutics, Inc. Botulinum toxin formulations and methods of use thereof in plantar fascitis with extended duration of effect
SG11202005239YA (en) * 2017-12-04 2020-07-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
JP7402799B2 (ja) 2017-12-22 2023-12-21 ウェスト ファーマ サービシーズ イスラエル リミテッド サイズの異なるカートリッジを利用可能な注射器
KR102088104B1 (ko) 2018-06-29 2020-03-11 호서대학교 산학협력단 개망초 꽃 에센셜 오일을 포함하는 신경 근육 관련 질환 예방 및 치료용 조성물
US20220031595A1 (en) 2018-12-03 2022-02-03 Eirion Therapeutics, Inc. Improved delivery of large agents
BR112021022619A2 (pt) 2019-05-14 2022-01-04 Eirion Therapeutics Inc Retardo de efeito de pico e/ou prolongamento de duração de resposta
CN114222754A (zh) 2020-03-31 2022-03-22 台湾浩鼎生技股份有限公司 A型肉毒杆菌毒素复合物、其配制剂和使用方法
US20230165946A1 (en) * 2020-04-08 2023-06-01 Medytox Inc. Botulinum toxin pre-filled injectable formulation that facilitates discharge rate control and is stable
US20230218498A1 (en) 2020-06-12 2023-07-13 Caregen Co, Ltd. Composition comprising pentapeptide as active ingredient
KR20220114183A (ko) * 2021-02-08 2022-08-17 주식회사 대웅 장기 저장이 가능한 보툴리눔 독소 동결건조 제형 조성물
WO2023239229A1 (ko) * 2022-06-10 2023-12-14 (주)메디톡스 보툴리눔 독소 안정화 조성물, 이를 포함하는 보툴리눔 독소 제제 및 이에 사용하기 위한 폴리펩티드

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
ES2347384T3 (es) 1993-12-28 2010-10-28 Allergan, Inc. Componente neurotoxico de una toxina botulinica para tratar de discinesia tardia.
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US20030095927A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
JP2002501033A (ja) 1998-01-26 2002-01-15 ユニバーシティー オブ マサチューセッツ Ａ型ボツリヌス菌の生物学的活性赤血球凝集素とその使用法
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6358917B1 (en) 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6544548B1 (en) * 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6844324B1 (en) 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
IL149778A0 (en) 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
DK1398038T4 (da) 2000-02-08 2011-03-28 Allergan Inc Lægemidler med botulinustoxin
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20030215412A1 (en) * 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
WO2002007773A2 (en) 2000-07-21 2002-01-31 Essentia Biosystems, Inc. Multi-component biological transport systems
US6787517B1 (en) 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US20020197278A1 (en) 2001-06-21 2002-12-26 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
DK1475101T3 (da) 2002-02-14 2011-01-10 Chugai Pharmaceutical Co Ltd Antistof-holdige farmaceutiske opløsninger
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20030224020A1 (en) 2002-05-31 2003-12-04 Zabudkin Alexander F. Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
RU2206337C1 (ru) 2002-10-29 2003-06-20 Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" Лекарственный препарат для лечения мышечных дистоний и способ его получения
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP5095388B2 (ja) 2004-03-03 2012-12-12 ルバンス セラピュティックス インク． ボツリヌストキシンの局所適用及び経皮送達のための組成物及び方法
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
CA2578250C (en) 2004-07-26 2013-03-05 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
EP1778279B1 (en) 2004-08-04 2014-12-03 Ipsen Biopharm Limited Pharmaceutical composition containing botulinum neurotoxin a2
PL1776137T3 (pl) 2004-08-04 2015-03-31 Ipsen Biopharm Ltd Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową
GB2419526A (en) 2004-10-28 2006-05-03 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
MXPA06009854A (es) * 2005-03-03 2007-03-29 Allergan Inc Sistema libre de productos de origen animal y proceso para purificar una toxina botulinica.
ES2362301T3 (es) * 2005-03-03 2011-07-01 Revance Therapeutics, Inc. Composiciones y procedimientos para aplicaciones tópicas y liberación transdérmica de un oligopéptido.
BRPI0608249A2 (pt) * 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
CN101228187A (zh) 2005-03-25 2008-07-23 特拉维夫大学拉莫特有限公司 针对突变p53的共同表位的人合成单链抗体及其用途
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
BRPI0618753A2 (pt) 2005-11-17 2011-09-13 Revance Therapeutics Inc composição para liberação transdérmica de toxina botulìnica e método de administração
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
JP2010514781A (ja) * 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法
KR20100020971A (ko) 2007-06-01 2010-02-23 메르츠 파마 게엠베하 운트 코. 카가아 고형 보툴리늄 톡신의 신경독 성분에 기초한 온도-안정한 근육 이완제를 제공하는 방법
KR102088949B1 (ko) * 2007-07-26 2020-03-13 레반스 테라퓨틱스, 아이엔씨. 항미생물 펩티드, 조성물, 및 이용 방법
WO2009056651A1 (en) 2007-11-02 2009-05-07 Cytos Biotechnology Ag Angiotensin-carrier formulation
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
KR20090120222A (ko) 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
TW201023928A (en) * 2008-11-12 2010-07-01 Kythera Biopharmaceuticals Inc Systems and methods for delivery of biologically active agents
CA2746425C (en) 2008-12-10 2016-05-03 Allergan, Inc. Clostridial toxin pharmaceutical compositions
DK2379104T3 (en) 2008-12-31 2018-04-30 Revance Therapeutics Inc Injectable botulinum toxin formulations
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US20120107361A1 (en) 2009-06-25 2012-05-03 Revance Therapeutics ,Inc. Albumin-Free Botulinum Toxin Formulations
ES2688065T3 (es) 2009-10-21 2018-10-30 Revance Therapeutics, Inc. Métodos y sistemas para purificar la neurotoxina botulínica no complejada
US20110106021A1 (en) 2009-10-30 2011-05-05 Revance Therapeutics, Inc. Device and Method for Topical Application of Therapeutics or Cosmetic Compositions
JP5990176B2 (ja) 2010-10-12 2016-09-07 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤
ES2641068T3 (es) 2011-01-07 2017-11-07 Revance Therapeutics, Inc. Composición tópica que comprende una toxina botulínica y un colorante
SI3241547T1 (sl) 2011-03-31 2020-10-30 Medy-Tox Inc. Liofiliziran pripravek botulinum toksina
US20130224268A1 (en) 2012-02-27 2013-08-29 Newgen Biopharma Corp. Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
RU2694820C9 (ru) 2014-12-23 2019-08-12 Мерц Фарма Гмбх Унд Ко. Кгаа Контейнер, предварительно заполненный ботулиновым токсином
SG11201810561YA (en) 2016-05-27 2018-12-28 Nestle Skin Health Sa Liquid neurotoxin formulation stabilized with tryptophan or tyrosine

Also Published As

Publication number Publication date
AU2016238949A1 (en) 2016-10-27
IL213668A0 (en) 2011-07-31
JP5866202B2 (ja) 2016-02-17
AU2009332947C1 (en) 2019-01-03
CN107343859A (zh) 2017-11-14
JP2012514003A (ja) 2012-06-21
CA2749757A1 (en) 2010-07-08
IL254558B (en) 2021-04-29
JP2019194251A (ja) 2019-11-07
AU2023229550A1 (en) 2023-11-23
CA2749757C (en) 2024-03-26
US20240058628A1 (en) 2024-02-22
ES2908616T3 (es) 2022-05-03
JP6145465B2 (ja) 2017-06-14
CN102300584A (zh) 2011-12-28
SG172812A1 (en) 2011-08-29
SG10202100698QA (en) 2021-02-25
AU2009332947A1 (en) 2011-07-07
BRPI0923731B1 (pt) 2024-02-06
US20110268765A1 (en) 2011-11-03
JP2022028770A (ja) 2022-02-16
IL254558A0 (en) 2017-11-30
US20100168023A1 (en) 2010-07-01
RU2011125775A (ru) 2013-02-10
KR101753242B1 (ko) 2017-07-20
KR20170077292A (ko) 2017-07-05
WO2010078242A1 (en) 2010-07-08
JP2017178954A (ja) 2017-10-05
AU2009332947B2 (en) 2016-07-07
DK3332805T3 (da) 2022-05-16
KR102179926B1 (ko) 2020-11-17
US20180214717A1 (en) 2018-08-02
HUE037595T2 (hu) 2018-09-28
EP2379104A4 (en) 2013-11-27
EP3332805A1 (en) 2018-06-13
JP6559849B2 (ja) 2019-08-14
MX2011007059A (es) 2011-09-15
US11471708B2 (en) 2022-10-18
BRPI0923731A2 (pt) 2016-01-19
AU2016238949C1 (en) 2018-11-01
AU2016238949B2 (en) 2018-07-26
US9956435B2 (en) 2018-05-01
HRP20180739T1 (hr) 2018-06-29
AU2021200561B2 (en) 2023-06-15
KR20190091376A (ko) 2019-08-05
IL281675A (en) 2021-05-31
PT2379104T (pt) 2018-03-26
EP2379104B1 (en) 2018-02-28
DK2379104T3 (en) 2018-04-30
ES2669020T3 (es) 2018-05-23
KR102363878B1 (ko) 2022-02-16
SG10201405582YA (en) 2014-10-30
LT2379104T (lt) 2018-04-10
JP6976997B2 (ja) 2021-12-08
HK1256878A1 (zh) 2019-10-04
US20200215357A1 (en) 2020-07-09
CY1120137T1 (el) 2018-12-12
NO2379104T3 (es) 2018-07-28
AU2018253620A1 (en) 2018-11-22
JP2018184460A (ja) 2018-11-22
KR20110117667A (ko) 2011-10-27
EP3332805B1 (en) 2022-02-23
AU2021200561A1 (en) 2021-02-25
EP2379104A1 (en) 2011-10-26
IL213668A (en) 2017-11-30
PL2379104T3 (pl) 2018-07-31
SI2379104T1 (en) 2018-05-31
JP2015134784A (ja) 2015-07-27
KR102005930B1 (ko) 2019-07-31
KR20200131348A (ko) 2020-11-23
AU2018253620B2 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
CO6400199A2 (es) Formulaciones inyectables de toxina botulínica
CO2018005361A2 (es) Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración
CL2012000269A1 (es) Formulacion farmaceutica inyectable subcutanea altamente concentrada de un anticuerpo anti-her2 que comprende dicho anticuerpo, un amortiguador, un estabilizador, un tensioactivo no ionico y una enzima hialuronidasa; dispositivo de inyeccion; kit y uso de la formulacion para tratar enfermedades tales como cancer.
BR112018008676A2 (pt) proteínas de fusão de fgf21 de ação prolongada e composição farmacêutica compreendendo as mesmas
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
BRPI0921002A8 (pt) Composições para tratamento bucal compreendendo sílica fundida e seu uso
CR10384A (es) Formulaciones de emulsion estable
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
NI201100025A (es) Métodos de administración de las formulaciones tópicas antimicóticas para el tratamiento de las infecciones por hongos.
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
BR112014019262A8 (pt) Composições orais veterinárias parasíticas compreendendo ingredientes ativos de ação sistêmica, métodos e uso das mesmas
WO2014143964A3 (en) Novel analgesic compositions
GT200700034A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
EA201001639A1 (ru) Композиции и способы их получения и применения
CR10927A (es) Composiciones y metodos de aplicacion topica y suministros transdermico de toxinas botulinum estabilizadas con fragmentos de polipeptido derivados de hiv-tat
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
CR9246A (es) Formulaciones terapeuticas del factor de crecimiento de queratinocitos
CO2020008231A2 (es) Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto
UY31780A (es) Fenoxibenzamidas sustituidas
ECSP10010588A (es) Formulacion de medicamento solida con liberacion retardada
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
EA201170512A1 (ru) Композиция для перорального введения
HN2011003403A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina

Legal Events

Date Code Title Description
FC Application refused